NASDAQ OMX

Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer

Dela

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, MD, as Chief Medical Officer.

Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical leadership experience, including over a decade within the diagnostics industry. Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical Officer, for Myriad Genetics, Inc., where he played a key leadership role and made substantial contributions across the company that helped drive and support a multi-fold increase in revenue over a decade. In addition to building and leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company's product development, M&A, and in-licensing activities. He also previously served as Chief Medical Officer for Myriad Genetic Laboratories, Inc.

"We are extremely pleased to welcome Rick to the team during this exciting time at Oxford Immunotec," said CEO, Dr. Peter Wrighton-Smith. "Rick's extensive leadership experience and the depth and breadth of his clinical, scientific, and commercial expertise will be immensely valuable as we continue to grow our core tuberculosis franchise and launch products into the new markets of tick-borne diseases, blood screening and transplantation."

Prior to joining Myriad Genetics, Dr. Wenstrup served as a tenured Professor of Pediatrics (Human Genetics) at Cincinnati Children's Hospital Medical Center and as a tenured Professor of Biomedical Engineering at the University of Cincinnati. During his time in academia, Dr. Wenstrup was principal investigator on multiple research grants from the National Institutes of Health (NIH) and the FDA Orphan Products Grant Program. He also served as a standing member of NIH review committees and on the scientific advisory boards of several disease-related foundations. Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children's Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics.  Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure.  The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market.  In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

CONTACTS:

For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec@westwicke.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Tier1CRM Receives Significant Equity Capital to Accelerate Growth11.12.2017 23:28Pressmeddelande

Raises $34 Million (USD) from Leading Financial and Strategic Investors to Continue Building on Recent Successes TORONTO and NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Tier1CRM (Tier1), a provider of cloud-based customer relationship management (CRM) solutions for the capital markets industry, announced today that it raised $34 million (USD) in growth equity financing from a group of investors led by Wavecrest Growth Partners, with participation from MassMutual Ventures and Salesforce Ventures. Founded in 2008 by Mark Notten and Phil Dias and based in Toronto, Tier1 is a leading provider of CRM and customer engagement SaaS solutions to sell-side and buy-side financial services clients spanning sales and trading desks, investment banks and investment managers. Major global financial institutions leverage the Tier1 platform to efficiently and more profitably manage client relationships, improve internal transparency and collaboration, manag

Minerva Neurosciences Names Richard Russell President11.12.2017 22:40Pressmeddelande

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell as President.  Dr. Remy Luthringer will continue as Chief Executive Officer of Minerva while resigning his position as President. Mr. Russell has more than 20 years of experience leading commercial operations, including developing and implementing sales and marketing activities for major biotechnology and pharmaceutical brands in North America and the European Union.  His experience encompasses several therapeutic areas, including CNS disorders, neurodegenerative disorders, cardiovascular disease and women's health. "We welcome Rick Russell to Minerva, where his wide-ranging commercial expertise will help ensure the effective transition from late-stage clinical development to the market for our product c

Sonoco-Alcore to Increase Paperboard Prices in Europe11.12.2017 22:30Pressmeddelande

BRUSSELS, Belgium, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sonoco-Alcore S.a.r.l. today announced it will again raise prices by a further €50 per tonne on all recycled paperboard grades sold in the Company's Central European regions. The price change is effective with shipments on or after the 1st January 2018. "The continued strong demand for core board across Europe, along with expectations that already elevated raw material and energy prices will continue to rise into the New Year, leave us little choice but to implement this increase," said Phil Woolley, Director - Paper Europe. Sonoco-Alcore S.a.r.l. is wholly-owned by Sonoco (NYSE:SON) and operates 29 tubes and cores plants and four paperboard mills in Europe. Contact: Roger Schrum +843/339-6018 roger.schrum@sonoco.com     This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corpor

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors11.12.2017 14:15Pressmeddelande

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of William F. Doyle and Hans Peter Hasler to the Board of Directors of the Company. "Bill Doyle and Hans Peter Hasler bring distinguished leadership backgrounds and complementary sets of expertise to Minerva's Board of Directors," said Dr. Fouzia Laghrissi-Thode, Board member and chairperson of the search committee at Minerva.  "Their bio-pharma industry-specific experience, which encompasses strategic development, partnering, licensing, product launches, marketing and commercialization, will benefit Minerva as the foundation is laid for the commercialization of the Company's products currently in advanced clinical development.  We look forward to Bill's and Hans's entrepreneurial and operational perspectives on how Minerva can b

Sabina Gold & Silver Announces Commencement of the Review of its Water License Applications for the Back River Project11.12.2017 13:30Pressmeddelande

VANCOUVER, British Columbia, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sabina Gold & Silver Corp (TSX:SBB.T), ("Sabina" or the "Company") is pleased to announce that the Nunavut Water Board (NWB) has commenced public review of the Type A and Type B water license applications related to initial development, mine construction and operation of the Back River Project (the "Project" or "Back River"). As announced on December 6, 2017, the Minister of Indigenous and Northern Affairs Canada, on behalf of the five responsible federal Ministers, accepted Nunavut Impact Review Board's recommendation for the Project to proceed to the regulatory and licensing phase.  The NIRB has advised that the final Project Certificate will be issued on or before January 4, 2018. The Type B water license would enable Sabina to commence certain initial pre-development activities in 2018 including onsite construction of service roads and laydown pads, and the mobilization of fuel, supplies and equipment at t

Standard Lithium Provides Development Update on California Lithium Project11.12.2017 11:00Pressmeddelande

VANCOUVER, British Columbia, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (FRA:S5L) (OTCQX:STLHF) is pleased to provide an update on the development work taking place at the Company's California Lithium Project; comprising the Bristol Dry Lake and the Cadiz Dry Lake lithium brine properties located in the Mojave Desert, California. A total of six new separate evaporation ponds have been installed on the Bristol Dry Lake Property to further assess the role that short-duration passive solar evaporation may play in processing the lithium brines encountered at the project.  Previous work demonstrated that, owing to extremely high evaporation rates in the project area, it is possible to concentrate brines from initial lithium concentrations of 146 mg/L to concentrations of 686 mg/L in approximately 7 weeks (note, this average lithium concentration was previously reported as 556 mg/L in news release dated 10th Oct 2017,

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum